The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2025 | Novel strategies being explored to improve outcomes for patients with EMD or PCL
Daniele Derudas, MD, Businco Hospital, Cagliari, Italy, comments on the novel strategies being explored to improve outcomes for patients with plasma cell leukemia (PCL) and extramedullary disease (EMD), highlighting that intensive treatment regimens are needed for patients with these aggressive forms of disease. This interview took place at the SOHO Italy Annual Conference 2025 in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
For the plasma cell leukemia, we had a trial with a KRd for the younger patient and older patients. It is very good treatment. But I think that the future is the immunotherapy, like the CAR-T cells and bispecifics. But to date, we have a little population that was treated with the CAR T-cells because of the aggressivity of the therapy, but this is the future because we need a response...
For the plasma cell leukemia, we had a trial with a KRd for the younger patient and older patients. It is very good treatment. But I think that the future is the immunotherapy, like the CAR-T cells and bispecifics. But to date, we have a little population that was treated with the CAR T-cells because of the aggressivity of the therapy, but this is the future because we need a response. We have some trials that incorporate the CAR T-cells in the treatment, in the pathway of treatment of the PCL patient.
What about the extramedullary disease? Again, the CAR T-cells and bispecifics, but I think that maybe the pomalidomide and the new antibodies, like the isatuximab, could be a good treatment. But the problem is in the patient with the plasma cell leukemia and extramedullary disease we need a trial, the trial that can incorporate the transplant, CAR-T, bispecifics for a very intensive treatment because the plasma cell leukemia and the extramedullary disease are an emergency for the patient with the multiple myeloma or the plasma cell dyscrasias.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
